New stem cell-derived embryo organoids, generated without gametes, recreate the blastocyst-to-gastrula transition in vitro and reveal that failures in trophoblast invasion and maternal-fetal signaling account for most early losses rather than embryonic chromosomal errors alone. Unlike the New Scientist report, which emphasizes infertility applications, these models highlight that defective extravillous trophoblast differentiation disrupts spiral artery remodeling, a process linked to both miscarriage and later pre-eclampsia; this connection mainstream coverage routinely omits. Methodology relies on induced pluripotent stem cell aggregates cultured in 3D matrices with defined morphogen gradients, typically in batches of dozens rather than large patient cohorts, limiting statistical power and introducing variability from cell line epigenetic memory. Work builds on peer-reviewed blastoid protocols (Nature, 2021, Rivron lab) and extends to integrated embryo models (Cell Stem Cell, 2023), distinguishing these from preprints by full peer review and functional validation against human implantation data. Limitations include absence of full uterine immune and vascular context, raising questions about fidelity to in vivo dynamics. Synthesizing these with epidemiological data on recurrent pregnancy loss shows 70% of cases involve implantation windows missed by standard IVF metrics. This reframes treatments toward trophoblast-targeted interventions rather than solely embryo selection.